echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Shenzhou Cell: Recombinant New Coronavirus Vaccine Product of Holding Subsidiary Received Drug Clinical Trial Approval

    Shenzhou Cell: Recombinant New Coronavirus Vaccine Product of Holding Subsidiary Received Drug Clinical Trial Approval

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 12th, Shenzhou Cell announced that recently, the company’s holding subsidiary, Shenzhou Cell Engineering, received the "Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration.


    SCTV01C is a recombinant new coronavirus Alpha+Beta mutant strain independently developed by Shenzhou Cell Engineering to address the problems of the first-generation domestic and foreign vaccines based on the original strain of the new coronavirus, such as the reduction of the neutralizing antibody titer and the protection rate of the mutant strain.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.